Jazz Pharmaceuticals PLC $JAZZ Stock Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 23.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,070 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,400 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Jazz Pharmaceuticals were worth $5,341,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp raised its position in Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after purchasing an additional 517,514 shares during the last quarter. Bank of America Corp DE boosted its stake in Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after purchasing an additional 99,656 shares during the period. Systematic Financial Management LP grew its position in Jazz Pharmaceuticals by 2.6% during the 1st quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after purchasing an additional 10,237 shares during the last quarter. Quantinno Capital Management LP grew its position in Jazz Pharmaceuticals by 9.7% during the 1st quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock worth $36,163,000 after purchasing an additional 16,928 shares during the last quarter. Finally, Tri Locum Partners LP acquired a new position in Jazz Pharmaceuticals in the first quarter valued at $29,995,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Renee D. Gala sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total value of $472,800.00. Following the completion of the sale, the chief executive officer directly owned 141,394 shares of the company’s stock, valued at $33,425,541.60. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total value of $1,500,780.00. Following the completion of the sale, the director owned 351,875 shares in the company, valued at approximately $88,014,493.75. This trade represents a 1.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 94,121 shares of company stock worth $23,337,922. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $215.98 on Monday. The company has a market cap of $14.02 billion, a price-to-earnings ratio of 14.90, a PEG ratio of 0.43 and a beta of 0.38. The firm’s 50-day simple moving average is $231.96 and its 200-day simple moving average is $216.24. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The company’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same period in the prior year, the company earned ($8.25) earnings per share. As a group, equities research analysts predict that Jazz Pharmaceuticals PLC will post 10.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on JAZZ. Deutsche Bank Aktiengesellschaft upped their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $276.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Morgan Stanley reduced their price objective on Jazz Pharmaceuticals from $322.00 to $314.00 and set an “overweight” rating for the company in a research note on Wednesday, October 21st. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a research note on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $292.05.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.